Physician profile
Scott Christopher Feudo
NPI 1184713885
$9,904.44
in general payments reported to CMS, 2019-2025
52 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $788 · 2021: $985 · 2022: $1,107 · 2023: $1,812 · 2024: $1,865 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,960.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,000.11 | 2020-2025 | |
| Glaxosmithkline, LLC. | $983.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $829.80 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $761.14 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $749.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $630.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $470.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.21 | 2019-2024 | Ofev, Tradjenta, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $327.03 | 2021-2025 | |
| Astellas Pharma US INC | $307.60 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $297.22 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $282.51 | 2019-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.01 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $229.89 | 2019-2023 | Airduo Digihaler, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $229.17 | 2019-2025 | Eliquis, Camzyos |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Feudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.